BioSpace News Archive

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a program to expand availability of Fluidigm® COVID-19 tests for U.S. colleges and universities.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at the virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting. The oral presentations will take place during the “Research Pipeline: New Findings on Diagnost

Research Solutions/Reprints Desk (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D driven organizations, today announced that it has partnered with BIO Business Solutions to help life sciences companies save time and money on scholarly literature access via its award-winning Article Galaxy research platform

Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier today announced topline results from GALACTIC-HF, a Phase 3 pivotal clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF).

Locanabio, Inc., a leader in engineering RNA-binding proteins that can target disease-causing mRNA using gene therapy delivery, today announced that Jim Burns , Ph.D., chief executive officer at the company, and Dimitrios G. Zisoulis, Ph.D., head of RNA biology and drug discovery, will participate in the following upcoming conferences:

Abveris, Inc. (“Abveris”) announced today that it has entered into an agreement with Immunitas Therapeutics, Inc. (“Immunitas”) for the discovery of monoclonal antibodies to expand the Immunitas therapeutic pipeline. Under the terms of the agreement, Abveris will utilize its proprietary DiversimAb TM mouse model in combination with

Datavant, the leader in helping life sciences and healthcare organizations safely connect their data while protecting patient privacy, today announced $40 million in Series B funding, bringing Datavant’s cumulative fundraising to $83 million.

Certara Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

- Recombinetics Inc., a leading gene editing company with platform technology in therapeutics development, today announced that it has merged its efforts with Makana Therapeutics, a leader in the field of xenotransplantation.

R3 Vascular Inc. today announced closing of its Series A financing round, including new equity investments of $15 million and the conversion of $2.8 million of convertible notes. The round was led by an unnamed corporate investor and 415 CAPITAL , with participation f